Orthopediatrics (NASDAQ:KIDS) Rating Lowered to Sell at BidaskClub
Several other research analysts have also issued reports on KIDS. Needham & Company LLC set a $69.00 price target on shares of Genomic Health and gave the stock a buy rating in a research report on Wednesday, June 19th. BTIG Research decreased their price target on shares of Verastem to $8.00 and set a buy rating on the stock in a research report on Friday, May 10th. Finally, Zacks Investment Research lowered shares of Hess Midstream Partners from a hold rating to a sell rating in a research report on Tuesday, May 14th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $46.75.
Shares of NASDAQ:KIDS opened at $35.54 on Tuesday. Orthopediatrics has a 12 month low of $25.11 and a 12 month high of $47.82. The business’s 50 day moving average price is $39.48. The company has a current ratio of 8.60, a quick ratio of 6.01 and a debt-to-equity ratio of 0.26.
A number of institutional investors have recently bought and sold shares of KIDS. BlackRock Inc. grew its position in Orthopediatrics by 12.4% during the 4th quarter. BlackRock Inc. now owns 455,657 shares of the company’s stock worth $15,894,000 after purchasing an additional 50,179 shares in the last quarter. FMR LLC grew its position in Orthopediatrics by 8.6% during the 4th quarter. FMR LLC now owns 414,600 shares of the company’s stock worth $14,462,000 after purchasing an additional 33,000 shares in the last quarter. RTW Investments LP purchased a new position in Orthopediatrics during the 4th quarter worth approximately $7,848,000. Prospect Capital Advisors LLC purchased a new position in Orthopediatrics during the 4th quarter worth approximately $7,136,000. Finally, Northern Trust Corp grew its position in Orthopediatrics by 30.8% during the 4th quarter. Northern Trust Corp now owns 135,143 shares of the company’s stock worth $4,713,000 after purchasing an additional 31,787 shares in the last quarter. Hedge funds and other institutional investors own 48.67% of the company’s stock.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Recommended Story: Commodities
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.